The Human Medicines Regulations 2012 – …

The Human Medicines Regulations 2012 – description of each Part This document provides a brief overview of each Part of the Human Medicines Regulations 2012 …

  Human, Regulations, Descriptions, Medicine, 2012, Human medicines regulations 2012, Human medicines regulations 2012 description of

FULTIUM -D 800 IU CAPSULES - GOV.UK

Vitamin D deficiency, with levels of 25(OH)D below 25nmol/L (10ng/ml), could result in the disease rickets (or osteomalacia). The disease resulting as a deficiency is considered to be due to malabsorption

  Deficiency, Capsule, Vitamin, Fultium d 800 iu capsules, Fultium, Vitamin d deficiency

GLYCOPYRRONIUM BROMIDE 0.2MG/ML …

UKPAR Glycopyrronium Bromide 0.2 mg/ml Solution for Injection PL 00156/0115 1 GLYCOPYRRONIUM BROMIDE 0.2MG/ML SOLUTION FOR INJECTION (PL 00156/0115)

  Solutions, Injection, 0115, Solution for injection pl 00156, 00156, Solution for injection, Pl 00156

Meloxicam - GOV.UK

PL 31388/0003-4 UKPAR Alpex Pharma (UK) Ltd, Meloxicam 7.5mg and 15mg Orodispersible Tablets 3 Scientific Discussion INTRODUCTION Based on the review of the data on quality, safety and efficacy, the UK granted

  15mg, Meloxicam

PL 00010/0643 - GOV.UK

UKPAR Canesten HC Cream PL 00010/0643 6 All excipients comply with their respective European Pharmacopoeia monographs, except triceteareth-4-

  Excipients, 3460, Pl 00010 0643, 00010

Public Assessment Report UKPAR Canesten Combi …

This is a summary of the Public Assessment Report (PAR) for Canesten Combi Pessary & External Cream 500mg / 2% w/w pessary & cream (PL 00010/0653).

DCPAR for Ampicillin-Salbactam 1 g--0 5 and 2 g-1 g ...

PAR Ampicillin/Sulbactam 1 g/0.5 g and 2 g/1 g powder for Solution for Injection or Infusion UK/H/4322/001-2/DC 1 Public Assessment Report Decentralised Procedure

  Solutions

Public Assessment Report Mutual Recognition …

PAR Sayana 104mg/0.65ml Suspension for Injection UK/H/0960/001/MR 1 Public Assessment Report Mutual Recognition Procedure SAYANA 104MG/0.65ML SUSPENSION FOR INJECTION

  Assessment, Report, Public, Procedures, Mutual, Recognition, Public assessment report mutual recognition, Public assessment report mutual recognition procedure

Cefixime 400 mg Film-coated Tablets, PL 22805 …

MHRA PAR; CEFIXIME 400 MG FILM-COATED TABLETS, PL 22805/0032-3 2 Lay summary The Medicines and Healthcare products Regulatory Agency …

  Cefixime

Public Assessment Report Decentralised Procedure …

Public Assessment Report Decentralised Procedure LIOTHYRONINE SODIUM 20 MICROGRAM TABLETS (liothyronine sodium) Procedure No: UK/H/6516/001/DC

  Assessment, Report, Public, Procedures, Public assessment report decentralised procedure, Decentralised

Package leaflet: Information for the patient Ranexa 375 mg ...

1 Package leaflet: Information for the patient Ranexa 375 mg prolonged-release tablets Ranexa 500 mg prolonged-release tablets Ranexa 750 mg prolonged-release tablets

  Release, Tablets, Prolonged, Mg prolonged release tablets

Tapentadol (Palexia®) prolonged and immediate release ...

November 2015 Tapentadol (Palexia®) prolonged and immediate release tablets for the treatment of acute and chronic severe pain. The New Therapies Subgroup of the Greater Manchester Medicines

  Release, Tablets, Immediate, Prolonged, Prolonged and immediate release tablets

Public Assessment Report Decentralised Procedure - GOV.UK

PAR Mariosea, Dengaff and Trillblad XL 2 mg and 4 mg Prolonged-release Capsules UK/H/4976/001-2/DC UK/H/4977-8/001/DC 2 LAY SUMMARY Mariosea XL 2 mg Prolonged-release Capsules

  Release, Capsule, Prolonged, Prolonged release capsules, Mariosea xl, Mariosea

AUSTRALIAN PRODUCT INFORMATION BETMIGA …

1 australian product information – betmiga® (mirabegron) prolonged-release film-coated tablets 1 name of the medicine mirabegron 2 qualitative and quantitative composition

  Release, Tablets, Coated, Film, Prolonged, Prolonged release film coated tablets

uk-mockup

PAGE 2 PAGE 3 • you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis